Sleep disorders (SD) in patients with dementia are very common in clinical practice. The use of antidepressants with hypnotic actions, such as trazodone, plays an important role in these cases. The aim of this study is to present a profile of the use of trazodone in demented patients with SD, as well as a review of trazodone hydrochloride in SD. We evaluated 178 elderly patients with Alzheimer's disease and other dementias, clinically presenting SD and treated with hypnosedative medications. In the one-year period comprising the study, 68 (38.2%) of the 178 had sleep disorders. Most patients (114; 64%) had a diagnosis of Alzheimer's disease. Approximately 85% of patients with SD used hypnosedative drugs. Trazodone was the most commonly used drug among patients (N = 35), with an effectiveness of 65.7%. Trazodone has been shown to be a good option for treatment of the elderly with dementia and associated SD. Key words: sleep, dementia, Alzheimer's disease, trazodone, antidepressant.
Sleep disorders are one of the major complications related to dementia and cause significant impacts on functionality and quality of life in elderly patients 1 .
These sleep disorders often contributes to institutionalization 2 . The origin of sleep disorders in dementia is usually multifactorial, resulting from pathophysiological changes associated with the disease itself, sensory deprivations such as a reduction in auditory and visual acuity, and changes in environmental stimuli such as light. Some studies have shown that damage to cholinergic neurons may contribute to changes in the sleep of patients with Alzheimer's disease (AD) 1 . Epidemiological surveys conducted in patients with AD have identified a prevalence of sleep disorders in up to 40% of patients with any stage of the disease 3 .
A longitudinal study conducted with 76 elderly demented patients over two years revealed that 24% of study participants used a hypnosedative drug chronically, increasing from 3 to 17% in the first year, and remaining high at 13% in the second year 4 . In the study of Grace and colleagues, in which the use of hypnosedative drugs was recorded in less than 30% of patients with sleep disorders, the authors argued that there was reluctance by doctors to use hypnotic drugs in demented patients with sleep disorders 5 . Appropriate treatment of sleep disorders may benefit both patients and their caregivers.
Antidepressants with hypnotic action, such as trazodone, have played important roles in treating the elderly with sleep disorders, particularly in patients with dementia 1 . The therapeutic dose to induce sleep using these drugs is much smaller than that used for depression, showing effectiveness in inducing sleep and little mood alteration effects.
Trazodone has proved to be effective in the treatment of sleep disorders in depressed patients (not always older) [6] [7] [8] , in secondary sleep disorders when compared to other substances 9, 10 and in healthy individuals 11 . Assessments of the clinical response to trazodone hydrochloride for the treatment of sleep disorders in demented patients may contribute to the pool of therapeutic options for these patients.
The objective of this analysis was to establish a profile of the use of hypnosedative drugs in demented patients with sleep disorders, with an emphasis on trazodone hydrochloride and its effectiveness. This is an open-label, uncontrolled, observational study. General data and specific analysis of sleep disorders have been the aims of another publication.
METHOD
This is a retrospective study that was previously approved by the Ethics Research Committee of the University of Brasilia. To be included, patients had to be diagnosed with dementia and followed for at least 12 months, during which time they were examined periodically every two months. The visits of each patient during 2008 and their records from visits in previous years since their first consultation were considered for selection and analysis. Among the 250 patients followed in the Geriatric The DSM-IV criteria 12 were used for the diagnosis of dementia and those of NINCDS-ADRDA 13 for AD (probable). Functionality was established using the Assessment of Instrumental Activities of Daily Life 14 . Mini Mental State Examination 15 and Clinical Dementia Rating (CDR) 16 were used in the cognitive assessment and in the characterization of the dementia stage, respectively.
The NPI (Nighttime Behavior) scale includes eight items that are rated as to how often they occurred during the past month 17 . Were considered to have a sleep disorder when all the following criteria: [1] Complaint of sleep disorder from patient or caregiver (NPI itemsnighttime behavior); [2] Exhaustion of caregiver (score ≥2; scale from 0 to 5, with 2 indicating mild distress).
Polysomnography and actigraphy were not performed, and structured sleep diaries were not requested because of the low educational level of patients and caregivers and the high proportion of patients with advanced degrees of dementia.
The presence of all of the items below (1 and 2) was the criterion for effectiveness in the treatment of sleep disorders: 1. Improvement of the sleep disorder complaint. 2. Reduction in the exhaustion of the caregiver in the item of NPI that deals with night behavior disorders for 1 (minimum) or 0 (absent).
The effectiveness percentile was calculated using the number of patients who showed evidence of improvement in their sleep disorder by the total number of patients treated with this drug. Adverse events were collected by spontaneous (unsolicited) reporting. Statistical analysis was performed using SPSS version 14.0 for Windows (SPSS, Chicago, USA). The data frequency was examined using the chi-squared test and t-tests were used to investigate baseline differences between genders. Statistical significance was set at p<0.05.
RESULTS
Approximately 2/3 of patients (64.6%) were women and the mean age of the sample cohort was 79.1+7.4 years. There was no difference between genders (p>0.05) with regards to average age. Most patients (114; 64%) had the diagnosis of AD.
The primary sleep disorder found among the elderly participants was difficulty in maintaining sleep at night (staying asleep). Difficulty in falling asleep, frequent arousals from sleep and early morning awakenings were observed. Although caregivers of our patients frequently complained about difficulties in sleep maintenance, the patients' sleep disorders could not be classified. Table 2 shows the most commonly used drugs for the treatment of sleep disorders in patients with dementia (some used more than one medication).
The other drugs (N=13) were combined into a single group known as "others", represented by benzodiazepines (triazolam, estazolam, and midazolam), antipsychotics (olanzapine and thioridazine) and non-benzodiazepine inducers (zolpidem).
The average time of use of antidepressants in months for the treatment of sleep disorders was 8.1 (±4) for trazodone, 18.6 (±10.1) for mirtazapine and 19.3 (±6.8) for mianserin.
Trazodone was used at a dose of 50 mg/day (at bedtime) in most patients (34) and 100 mg/day in one patient. No adverse effects were reported (spontaneously).
In the cases where non-effectiveness of treatment was experienced (12), such non-effectiveness was observed from the first days of treatment, except for one case in which non-effectiveness began after 5 months of drug use.
DISCUSSION
Trazodone is among the antidepressants used with good tolerability in this sample, showing effectiveness in 2/3 of patients.
Antidepressants are a suitable option for the treatment of sleep disorders in the elderly 18 . Tricyclic antidepressants such as amitriptyline, imipramine and cloimipramine, have been used to induce sleep in patients without dementia, especially when the sleep disorder is associated with depression 19 . However, their anticholinergic action may lead to impaired cognition and risk of mental confusion.
Trazodone offers a dual action on serotonin receptors by blocking serotonergic receptor 2A (5HT2A) and inhibiting serotonin reuptake. Phenylpiperazines are differentiated from tricyclic antidepressants since they show greater selectivity for 5HT2A receptors. With regard to the blocking of serotonin reuptake, trazodone is less potent than tricyclic antidepressants or selective serotonin reuptake inhibitors (SSRIs), and also blocks alpha 1 receptors. There is also a blockade of histaminergic receptors, thus differing from nefazodone; this blocking of histaminergic receptors may be responsible for the extreme sedative effect of this drug. As a result of sleepiness induced as a side-effect, even with off-label use, trazodone has been used in various circumstances in which the main goal is sleep induction 20 , but not in dements patients. Trazodone has also been used as an adjuvant to other antidepressants because it increases the tolerabili- Sleep onset latency Trazodone: sleep disorders in dementia Camargos et al.
ty of these antidepressant by working to reduce their induced adverse effects via the blocking of 5HT2A receptors (stimulated by SSRI) 21 . The classic indication of trazodone is for depression, particularly when anxiety and insomnia are also present. The usual daily dose for improvement of the sleep disorder complaint varies between 150 and 200 mg/day. Extreme doses of 50 and 600 mg/day may be used in specific cases. Lower doses, between 25 and 100 mg/day, have been prescribed as a hypnosedative for patients with insomnia and to correct the adverse effects of insomnia caused by SSRIs 22 . Due to its relative safety and its low inhibition of cholinergic receptors, trazodone has been used in the treatment of depression in elderly patients with cardiovascular disease. Reduced anticholinergic effect allows its use in elderly patients with cardiovascular impairments and delirium.
Most studies evaluating trazodone in the treatment of sleep disorders were conducted in patients with depression. Saletu-Zyhlarz and collaborators, using polysomnography, evaluated 11 individuals with depression and sleep disorders and compared them to 11 healthy subjects. The authors observed an improvement in sleep parameters with the use of 100 mg/day of trazodone 23 . There was an increase in sleep total time, as we well as a reduction in nighttime and early awakenings. This study also reported improvements in the subjective quality of sleep, sleep efficiency, numerical memory and somatic complaints. This improvement in memory may be welcomed in cases of patients with dementia. In our study, the patients did not use trazodone at doses higher than 100 mg/day, which may have contributed to a lower effectiveness when compared to mirtazapine. There appears to be some improvement in sleep parameters with increasing doses of trazodone 6, 7, 10 . Nierenberg and colleagues reported good in subjective sleep parameters (PSQI -Pittsburgh Index) with the use of 50 mg/day of trazodone while evaluating patients with secondary insomnia with the use of antidepressants 24 . Similar findings were observed by Kaynak using trazodone at a dose of 100 mg/day, with subjective and objective improvement of quality of sleep after one week of treatment 10 . Despite the improvement in sleep parameters reported in most studies, polysomnographic findings vary among studies, probably due to differences in the dose used and age of the participants (Table 3) .
Trazodone has been shown to be effective in the elderly population mainly due to associated reduced anticholinergic effects and undetectable electrocardiographic changes. Another important aspect of this drug is its good tolerability as a treatment for depression in elderly patients. In the current study, 1/3 terminated treatment with trazodone due to a lack of effectiveness but not due to adverse effects. The study of Lebert and colleagues showed no increase in adverse effects of trazodone in patients with dementia 25 . The mechanism involved in the sedative effect of some antidepressants, among them trazodone, remains unclear. It is not known whether there is an improvement in sleep due to an improvement in depression or whether the improved sleep is due to the direct action of the medication 11 . Kaynak and collaborators suggest that the therapeutic effect of trazodone on sleep is independent of its antidepressant effect 10 .
Trazodone and other antidepressants with strong antagonism of 5-HT2 receptors have properties that increase the slow-wave sleep in healthy volunteers and in depressed patients with insomnia 26 . The risk of priapism and trazodone-related cardiac arrhythmia is low and is only associated with high doses. The alpha-adrenergic blockade caused by trazodone is thought to the mechanism responsible for priapism 22 . Limitations of this study include: absence of an instrument to ensure that all patients met diagnostic criteria for sleep disorders; the lack of a double-blind design; drugs eligibility was determined on the basis of physician's clinical judgment, because this study sought to reflect the manner in which physicians treat SD in dement elderly; information regarding the effectiveness of these drugs cannot be so clearly, since different drugs might be selected for different purposes. For example, a highly effective drug might look ineffective since doctors might tend to use it only in the most refractory patients; absence of a placebo control group, it is not possible to draw definitive conclusions as one might with a randomized, blinded trial; under-reporting is a recognized limitation of studies based upon spontaneous adverse event reporting.
Nonetheless, the results of this study, in an apparently representative cohort of demented elderly, provide useful and clinically relevant information. This study was intended to show the effectiveness of drugs (trazodone, specially) to SD in demented elderly under 'real world' conditions and make a review. References are cited spanning at least three decades of research.
According to Erman, the lack of studies on the chronic use of trazodone is a reflection of the lack of interest by health authorities and pharmaceutical industries to develop controlled studies with placebo and doubleblind groups to assess the effectiveness and safety of the drug in these patients, since the drug has no more patent reserves 27 . The literature reveals the need for controlled, prospective, double-blind and randomized studies to evaluate the benefits of trazodone in this particular segment of the population with dementia 20, 28, 29 .
